PMID- 33395782 OWN - NLM STAT- MEDLINE DCOM- 20210115 LR - 20240330 IS - 1878-0334 (Electronic) IS - 1871-4021 (Print) IS - 1871-4021 (Linking) VI - 14 IP - 6 DP - 2020 Nov-Dec TI - New onset diabetes, type 1 diabetes and COVID-19. PG - 2211-2217 LID - S1871-4021(20)30477-X [pii] LID - 10.1016/j.dsx.2020.11.012 [doi] AB - BACKGROUND AND AIMS: New data has emerged regarding higher risk of coronavirus disease 2019 (COVID-19), and its severity and complications in patients with type 2 diabetes mellitus (T2DM). However, there is a dearth of evidence regarding type 1 diabetes mellitus (T1DM). This article explores the possibility of COVID 19 induced diabetes and highlights a potential bidirectional link between COVID 19 and T1DM. METHODS: A literature search was performed with Medline (PubMed), Scopus, and Google Scholar electronic databases till October 2020, using relevant keywords (COVID-19 induced diabetes; COVID-19 and type 1 diabetes; COVID-19 induced DKA; new-onset diabetes after SARS-CoV-2 infection) to extract relevant studies describing relationship between COVID-19 and T1DM. RESULTS: Past lessons and new data teach us that severe acute respiratory syndrome coronaviruses (SARS-CoV and SARS-CoV-2) can enter islet cells via angiotensin converting enzyme-2 (ACE-2) receptors and cause reversible beta-cell damage and transient hyperglycemia. There have been postulations regarding the potential new-onset T1DM triggered by COVID-19. This article reviews the available evidence regarding the impact and interlink between COVID-19 and Tau1DM. We also explore the mechanisms behind the viral etiology of Tau1DM. CONCLUSIONS: SARS-CoV-2 can trigger severe diabetic ketoacidosis at presentation in individuals with new-onset diabetes. However, at present, there is no hard evidence that SARS-CoV-2 induces T1DM on it's own accord. Long term follow-up of children and adults presenting with new-onset diabetes during this pandemic is required to fully understand the type of diabetes induced by COVID-19. CI - Copyright (c) 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. FAU - Boddu, Sirisha Kusuma AU - Boddu SK AD - Department of Pediatric Endocrinology, Rainbow Children's Hospital, Hyderabad, India. FAU - Aurangabadkar, Geeta AU - Aurangabadkar G AD - Department of Endocrinology, CARE Multispecialty Hospital, Hyderabad, India. Electronic address: vrgeeta@yahoo.com. FAU - Kuchay, Mohammad Shafi AU - Kuchay MS AD - Division of Endocrinology and Diabetes, Medanta the Medicity Hospital, Haryana, India. LA - eng PT - Journal Article PT - Review DEP - 20201117 PL - Netherlands TA - Diabetes Metab Syndr JT - Diabetes & metabolic syndrome JID - 101462250 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - EC 3.4.17.23 (ACE2 protein, human) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) SB - IM MH - Angiotensin-Converting Enzyme 2/antagonists & inhibitors MH - Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use MH - COVID-19/*diagnosis/*mortality MH - Diabetes Mellitus, Type 1/*diagnosis/drug therapy/*mortality MH - Humans MH - COVID-19 Drug Treatment PMC - PMC7669477 OTO - NOTNLM OT - ACE2 receptors OT - Hyperglycemia OT - New-onset diabetes OT - SARS-CoV-2 OT - Type 1 diabetes OT - beta-cell damage COIS- Declaration of competing interest The authors declare that there are no conflicting interests relevant to this article. EDAT- 2021/01/06 06:00 MHDA- 2021/01/16 06:00 PMCR- 2020/11/17 CRDT- 2021/01/05 01:04 PHST- 2020/10/17 00:00 [received] PHST- 2020/11/09 00:00 [revised] PHST- 2020/11/11 00:00 [accepted] PHST- 2021/01/05 01:04 [entrez] PHST- 2021/01/06 06:00 [pubmed] PHST- 2021/01/16 06:00 [medline] PHST- 2020/11/17 00:00 [pmc-release] AID - S1871-4021(20)30477-X [pii] AID - 10.1016/j.dsx.2020.11.012 [doi] PST - ppublish SO - Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2211-2217. doi: 10.1016/j.dsx.2020.11.012. Epub 2020 Nov 17.